Hovione New Jersey welcomes a Team from the FDA for a Training on Continuous Manufacturing
Hovione New Jersey welcomes a Team from OPQ of the FDA as part of the Experiential Learning Site Visit Program for a Training on Continuous Manufacturing.
The main objective was to understand the technology and the science behind it, how does industry apply it and which challenges industry faces. The main purpose was to provide the FDA team a better understanding of drug development and manufacturing processes with continuous manufacturing.
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
in-PharmaTechnologist, September 3, 2019
Pharmaceutical Technology, September 2, 2019
Loughbeg, Co. Cork. Thursday, September 5th, 2019: Hovione is celebrating its 60th Anniversary today in its site in Cork.